• 1
    Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013; 11: 88.
  • 2
    Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol 2013; 9: 7792.
  • 3
    Lankarani KB. Mortality associated with infliximab. J Clin Gastroenterol 2001; 33: 2556.
  • 4
    de' Clari F, Salani I, Safwan E, Giannacco A. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation 2002; 105: E183.
  • 5
    Scheinfeld N. Off-label uses and side effects of infliximab. J Drugs Dermatol 2004; 3: 27384.
  • 6
    Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infliximab infusions are safe. Aliment Pharmacol Ther 2013; 38: 36576.
  • 7
    Carrascosa JM. Immunogenicity in biologic therapy: implications for dermatology. Actas Dermosifiliogr 2013; 104: 4719.
  • 8
    Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 117283.
  • 9
    Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108: 407.